Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
New in the 10-K 16 paragraphs with nothing like them in the 10-K filed Feb 19, 2025 New in the 10-Q 48 paragraphs not in the 10-Q filed Aug 5, 2026 10-Q against the 10-K 71 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 19, 2025. A box jumps to the paragraph as filed, below.

16 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

16 paragraphs in Risk Factors of the 10-K filed Feb 18, 2026 with nothing like them in the 10-K filed Feb 19, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

•Our future financial performance depends on the successful commercialization of our products and product candidates.

Read in the 10-K

•Changing regulatory standards may make it difficult to accurately predict the likelihood of obtaining marketing approval.

Read in the 10-K

•We may experience unexpected costs or not achieve our anticipated savings from our recently announced strategic restructuring plan.

Read in the 10-K

Our future financial performance depends on the successful commercialization of our products and product candidates.

Read in the 10-K

or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.

Read in the 10-K
Show the other 6

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Changes in the leadership of the FDA and other federal agencies under the current administration, including return-to-office policy, hiring freeze, and other policies, may lead to changes in the operations of the FDA, which may have a material impact on the industry and our clinical development plans. There have been widespread layoffs across various governmental agencies, including at the FDA, and other employees, including senior leaders at certain agencies, have resigned in response to the reforms, the full impact of which is unclear at this time. In addition, there is uncertainty around the funding, functioning and policy priorities of various governmental agencies, including the FDA. Disruptions or changes in how the FDA operates due to these policies could result in delays in FDA review or approval of our product candidate applications. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Further, applications for our product candidates could fail to receive regulatory approval, or could be delayed in receiving regulatory approval, for several other reasons, including but not limited to the following:

Read in the 10-K

As we increase the number and range of our commercialized products, particularly as we prepare for launches of our first gene therapy products, we will need to expand our commercial and support teams to include additional expertise in those products. We may also experience additional complexities in our sales process and strategy and may encounter difficulties in allocating sufficient resources to sales and marketing of certain products. Further, as we launch additional products or as demand for our products change, our initial estimate of the size of the required field force may be materially more or less than the size of the field force

Read in the 10-K

drugs, surgical procedures, and other treatments in particular, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

Read in the 10-K

Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.

Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators. For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary. As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.

In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In June 2024, the Supreme Court overruled the Chevron doctrine, which had given deference to regulatory agencies’ statutory interpretations of ambiguous regulations in litigation against federal government agencies, such as the FDA. The overruling of the Chevron doctrine may significantly increase the number of challenges brought by companies and other stakeholders against federal agencies such as the FDA and its longstanding decisions and policies, including the FDA’s statutory interpretations of market exclusivities and the “substantial evidence” requirements for drug approvals, which could undermine the FDA’s authority, lead to uncertainties in the industry, and disrupt the FDA’s normal operations, any of which could delay the FDA’s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.

In January 2025, an executive order entitled “Unleashing Prosperity Through Deregulation,” was issued which calls for at least 10 existing regulations to be repealed whenever an executive department or agency publicly proposes for notice and comment or otherwise promulgates a new regulation. Recent developments at the FDA include announcement of a plan to phase out animal testing for monoclonal antibodies and certain other drugs, the proposed rare disease evidence principles (RDEP) program to facilitate approval of drugs to treat rare diseases with very small patient populations with significant unmet medical need and with a known genetic defect that is the major driver of the pathophysiology, and the announcement of a new Commissioner’s National Priority Voucher program for companies supporting certain U.S. national health priorities and interests. To the extent our competitors are selected for this new voucher pilot program, or are otherwise able to participate in any of these initiatives intended to accelerate drug development and application review, and obtain faster approval than us, our competitive position may be harmed. The FDA has also increased its scrutiny of foreign drug manufacturing facilities and other contractors based in China, especially with respect to the transfer of biological materials, genetic data, and other sensitive data of American patients to parties located in China. It is unclear how our industry and our clinical programs will be impacted by policies and regulations implemented under the current administration and FDA leadership, or other executive orders. There is significant uncertainty in the industry and how federal agencies like the FDA will change in the coming years under the current administration. To the extent the agency reorganization and other agency changes lead to disruptions in the FDA’s operations, our correspondence and regulatory review processes with the FDA may be materially delayed.

Read in the 10-K

Increasing use of social media could give rise to liability and result in harm to our business.

Read in the 10-K

We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our recently initiated strategic restructuring plan.

In February 2026, we initiated a strategic restructuring plan, which includes a 10% workforce reduction of approximately 130 employees across the company. Our workforce reduction may cause disruptions to our business operations. For example, the workforce reduction has resulted in the loss of a number of long-term employees, the loss of institutional knowledge and expertise and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect employee morale and our operations. In addition, we may not be able to achieve the anticipated benefits or effectively realize all the cost savings anticipated from the reduction in force and we may incur unanticipated charges or make additional cash payments as a result of such initiatives that were not previously contemplated which could result in an adverse effect on our business or results of operations.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before

New in the latest 10-Q

48 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

• our ability to successfully launch and commercialize our recently approved gene therapy products, FAYUVI (formerly UX111) and GENGLYCOS (formerly DTX401), including our ability to manufacture and supply both products, establish qualified treatment centers, fulfill applicable post-marketing requirements and maintain regulatory approvals, including the accelerated approval of GENGLYCOS;

Read in the 10-Q

Financial statements and notes

Nine Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Operating activities: Net loss $(395) $(446) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 98 116 Amortization of discount on marketable securities, net (1) (4) Depreciation and amortization 25 26 Non-cash royalty revenue (81) (74) Non-cash interest expense on liabilities for sales of future royalties 63 42 Deferred income taxes (10) — Other (2) (3) Changes in operating assets and liabilities: Accounts receivable (20) 3 Inventory (8) (6) Prepaid expenses and other assets 2 (7) Accounts payable, accrued, and other liabilities (8) (13) Net cash used in operating activities (337) (366) Investing activities: Purchase of property, plant, and equipment (4) (5) Purchase of marketable securities (227) (32) Proceeds from sale of marketable securities 91 — Proceeds from maturities of marketable securities 200 362 Payments for intangible asset (5) (15) Other (2) (2) Net cash provided by investing activities 53 308 Financing activities: Proceeds from issuance of simple agreements for future equity, or SAFEs 10 — Proceeds from the issuance of common stock under equity plans, net 3 4 Proceeds from the issuance of common stock in connection with at-the-market offering, net — 80 Net cash provided by financing activities 13 84 Effect of exchange rate changes on cash (1) 5 Net (decrease) increase in cash, cash equivalents and restricted cash (272) 31 Cash, cash equivalents and restricted cash at beginning of period 436 184 Cash, cash equivalents and restricted cash at end of period $164 $215

Read in the 10-Q

2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. The Company consolidates any variable interest entity, or VIE, for which it is the primary beneficiary. Certain reclassifications have been made to prior periods in the Condensed Consolidated Financial Statements and accompanying notes to conform with the current presentation. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited interim Condensed Consolidated Financial Statements have been prepared on the same basis as the annual financial statements. In the

Read in the 10-Q

Accrued Liabilities Accrued liabilities consist of the following (in millions): September 30, December 31, 2026 2025 ─────────────────────────────────────────────────────────────────────────────────────────────── Research and clinical study expenses $ 22 $ 23 Payroll and related expenses 74 89 Revenue related reserves 80 57 Manufacturing and related expenses 42 67 Other 24 29 Total accrued liabilities $ 242 $ 265 Intangible Assets Upon FDA approval of GENGLYCOS in August 2026, the Company reclassified $41 million of acquired in-process research and development from an indefinite-lived intangible asset to a finite-lived intangible asset. The Company began amortizing the asset on a straight-line basis over its estimated useful life of seven years, with amortization recorded in cost of sales. Amortization expense was nominal for the three and nine months ended September 30, 2026.

Read in the 10-Q

In July 2026, Amlogenyx issued two SAFEs for aggregate proceeds of $10 million. One SAFE for $5 million was issued to Dr. Emil Kakkis, the Company’s Chief Executive Officer and a related party, and one for $5 million was issued to an unaffiliated investor on the same terms. The SAFEs convert into Amlogenyx equity at a 30% discount to the price paid in Amlogenyx's next equity financing. The SAFEs have no valuation cap, no stated maturity date and carry no voting or board rights. The SAFEs are accounted for as freestanding liabilities, included in other current liabilities, and remeasured at fair value through other income. No changes in fair value were recognized during the three or nine months ended September 30, 2026.

Read in the 10-Q
Show the other 43

and sales milestones. The Company may share in certain costs for global trials led by Regeneron. Additionally, the Company pays Regeneron a product purchase price and royalties on certain revenues.

Read in the 10-Q

The Company had collaboration payables for this arrangement included in accrued liabilities on the Condensed Consolidated Balance Sheets of $7 million and $9 million as of September 30, 2026 and December 31, 2025, respectively.

Read in the 10-Q

The following table shows the activity within the liability account (in millions): Liabilities for Sales of Future Royalties OMERS 2025 OMERS 2022 RPI 2019 Total December 31, 2024 $ - $ 495 $ 375 $ 870 Net proceeds from sale of future royalties 392 - - 392 Royalty revenue - (79) (29) (108) Non-cash interest expense 6 36 20 62 December 31, 2025 398 452 366 1,216 Royalty revenue - (70) (23) (93) Non-cash interest expense 27 23 13 63 September 30, 2026 $ 425 $ 405 $ 356 $ 1,186

Read in the 10-Q

restricted stock units, and performance stock units Employee stock purchase plan 0.1 0.1 - 0.1 18.6 16.8 17.4 17.0

Read in the 10-Q

14. Subsequent Events Sale of Priority Review Vouchers In October 2026, the Company entered into agreements to sell the PRVs received upon FDA approval of GENGLYCOS and FAYUVI for $210 million and $203 million, respectively. The sale of the GENGLYCOS PRV closed in October 2026. The Company is obligated to pay the National Institutes of Health, or NIH, $42 million from the sale of the PRV received from GENGLYCOS approval pursuant to the terms of a license agreement with the NIH. The Company expects to reflect net proceeds of $164 million, after payment to NIH and related fees. The closing of the FAYUVI PRV sale is expected to occur by year end 2026, subject to satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Company is also obligated to pay to a third-party licensor $16 million from the sale of the PRV received upon FDA approval of FAYUVI per the terms of a license agreement entered into on October 26, 2026, pursuant to which the Company obtained an exclusive license, in the field of MPS IIIA, to certain of the licensor’s patents and patent applications. The Company expects to receive net proceeds of $185 million upon the closing of the FAYUVI PRV sale. Restructuring Plan

Read in the 10-Q

In October 2026, the Company’s Board of Directors approved a restructuring plan that includes a reduction of approximately 20% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will incur restructuring charges of approximately $25 million in total in connection with employee related termination and severance costs and other activities.

Read in the 10-Q

GENGLYCOS, formerly known as DTX401, is an adeno-associated virus serotype 8, or AAV8, gene therapy administered by IV that delivers a functional copy of the G6PC gene to restore glucose-6-phosphatase activity developed for the treatment of GSDIa. GSDIa is an ultra-rare genetic metabolic disorder caused by a deficiency of the enzyme needed to release glucose from the liver to the bloodstream. The deficiency reduces the liver’s ability to control glucose levels and is associated with potentially life-threatening hypoglycemia episodes and other serious complications, requiring rigorous nutritional management that involves a burdensome, around-the-clock regimen of raw cornstarch intake as an oral glucose replacement therapy. Glucose control with cornstarch is crude with large swings in glucose, and patients instead end up spending a large fraction of their day significantly hyperglycemic to avoid hypoglycemic episodes. GSDIa affects 1,500 to 2,500 patients in the U.S. and 6,000 to 8,000 worldwide within commercially accessible geographies.

Read in the 10-Q

FAYUVI, formerly known as UX111, is an adeno-associated virus 9, or AAV9, gene therapy, administered by a one-time IV infusion that provides the cross-correcting enzyme that enables the breakdown of Heparan sulfate developed for the treatment of MPS IIIA. MPS IIIA is an ultra-rare, fatal lysosomal storage disease that primarily affects the brain and is marked by rapid, progressive neurodegeneration beginning in early childhood. Children with MPS IIIA typically experience progressive global developmental delay, followed by the loss of cognitive, language, and motor function, ultimately leading to early death. MPS IIIA is estimated to affect approximately 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years.

Read in the 10-Q

In August 2026, we announced the FDA granted accelerated approval for GENGLYCOS, in adult and pediatric patients eight years and older with GSDIa. We also received a Rare Pediatric Disease Priority Review Voucher (PRV) upon this approval.

Read in the 10-Q

In October 2026, we entered into a definitive agreement to sell the PRV we received upon GENGLYCOS approval for a sales price of $210 million. The sale was completed on October 30, 2026.

Read in the 10-Q

In October 2026, we entered into a definitive agreement to sell the PRV we received upon FAYUVI approval for a sales price of $203 million.

Read in the 10-Q

In November 2026, we announced that additional data in the dose-finding, stage of the Cyprus2+ study of UX701 for the treatment of Wilson disease, including data from the fourth dosing cohort, demonstrated clinical activity in some patients, but did not meet our criteria we had set to advance the program to the pivotal, Phase 3, stage of development. UX701 demonstrated a favorable safety profile across all cohorts dosed.

Read in the 10-Q

We will terminate further development of this program and are working with clinical sites and patient advocacy groups to support the patient community through this transition.

Read in the 10-Q

In September 2026, we announced results from the Phase 3 Aspire study for apazunersen in Angelman syndrome. The study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI). The safety profile observed in the Aspire study was consistent with Phase 1/2.

Read in the 10-Q

In Aspire, the randomized groups were comparable at baseline and consistent with the patients studied in Phase 2. There were no differences between the treated and control groups that could support efficacy in the Bayley Cognition raw scores nor in the MDRI when looking at net response or mean changes of the individual five endpoints included in the MDRI.

Read in the 10-Q

We are winding down this program and are working with clinical sites and patient advocacy groups to support the patient community through this transition.

Read in the 10-Q

We expense costs associated with the manufacture of our products prior to regulatory approval. Capitalization of such costs begins upon regulatory approval of the product for batches commenced after that date. Prior to FDA approval of GENGLYCOS in August 2026 and FAYUVI in September 2026, manufacturing and related costs for those products were expensed as research and development; accordingly, those costs were not capitalized and are not reflected in cost of sales after the respective approval dates. We expect inventory balances to increase as we produce products and capitalize the full costs of manufacturing, and we expect cost of sales to increase in relation to product revenues as we deplete the previously expensed inventory.

Read in the 10-Q

Inventory manufactured after regulatory approval is valued at the lower of cost and net realizable value, and cost is determined using the average cost method. Fixed production overhead is allocated to inventory based on the normal capacity of our manufacturing facilities. Overhead in excess of the amount allocated on that basis is recognized in cost of sales in the period incurred and is not capitalized.

Read in the 10-Q

We periodically review our inventories for excess amounts or obsolescence and write down obsolete or otherwise unmarketable inventory to estimated net realizable value.

Read in the 10-Q

Manufacturing costs incurred prior to approval for GENGLYCOS and FAYUVI were recorded as research and development expense. We estimate the cost of the inventory manufactured prior to approval, and expensed as research and development as of September 30, 2026, at approximately $88 million for FAYUVI and $113 million for GENGLYCOS.

Read in the 10-Q

Fixed manufacturing overhead was not allocated to individual production runs before approval, because no inventory was capitalized in those periods. We have therefore estimated the cost of this inventory by applying manufacturing overhead from a representative period of normalized production to the batches comprising the inventory on hand at approval.

Read in the 10-Q

There were no sales of GENGLYCOS or FAYUVI during the three and nine months ended September 30, 2026, and as a result there was no impact on cost of sales from the inventory manufactured and expensed prior to approval.

Read in the 10-Q

GENGLYCOS and FAYUVI are each administered as a single infusion at a dose determined by the patient's body weight. The number of vials required to treat a patient, and accordingly the cost of goods attributable to that patient, varies materially with patient weight. As a result, cost of sales as a percentage of the related product revenue will vary from period to period with the weight profile of the patients treated in that period, and will continue to do so after the previously expensed inventory has been fully consumed.

Read in the 10-Q

As the number of patients who can be treated from this inventory depends on their weights, the period in which inventory manufactured prior to approval is fully consumed may differ significantly from our estimates. We currently estimate that the inventory manufactured prior to approval will be fully consumed around the end of 2027 for FAYUVI and around the end of 2028 for GENGLYCOS. The actual consumption period will also depend on demand, the number of patients treated, the weight of the patients, the use of this inventory to supply our patient access and compassionate use programs, which draw on the same supply as commercial demand, and expiration dating.

Read in the 10-Q

We expect our gross margin percentage to decrease as we sell products that reflect the full cost of manufacturing and as we deplete the inventory expensed prior to approval.

Read in the 10-Q

is invested with a view toward liquidity and capital preservation, and we seek to minimize the potential effects of concentration and credit risk.

Read in the 10-Q

Subsequent to September 30, 2026, we announced the sale of the PRVs received upon the approvals of GENGLYCOS and FAYUVI. The GENGLYCOS PRV sale closed on October 30, 2026. The sale of the FAYUVI PRV remains subject to satisfaction of customary closing conditions and is expected to occur prior to the end of 2026. We expect to receive combined net proceeds of $349 million from the sale of both PRVs.

Read in the 10-Q

Legal proceedings

In August 2026, we entered into a settlement agreement with Esjay, and in October 2026, we entered into a settlement agreement with Navinta. Under these settlement agreements, each of Esjay and Navinta may market its generic version of DOJOLVI in the U.S. beginning January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted for DOJOLVI, subject to certain conditions and exceptions customary for such agreements, which could result in an earlier entry date.

Read in the 10-Q

Our litigation against the remaining defendants - Aurobindo, Somerset, and Sun Pharma - is ongoing.

Read in the 10-Q

Risk Factors

• We have a history of operating losses and may not achieve profitability on our expected timeline or at all.

Read in the 10-Q

• Our ability to successfully commercialize our recently approved gene therapy products.

Read in the 10-Q

We have a history of operating losses and may not achieve profitability on our expected timeline or at all.

Read in the 10-Q

Following the approvals of GENGLYCOS and FAYUVI and the failure of the GTX-102 Aspire Phase 3 study, which reduced the number of late-stage programs that may generate near-term value, we expect investors to evaluate us increasingly on the commercial performance of our approved products, with less weight on clinical and regulatory milestones. Our commercial performance depends on several products that face different risks. A substantial portion of our total revenue consists of royalty revenue from KKC's sales of CRYSVITA, which depends on KKC's commercialization efforts, which we do not control. See risk factor “We are dependent on KKC for the d commercialization of CRYSVITA in our markets, including the U.S. and Canada, and for our supply of CRYSVITA in our markets.” GENGLYCOS and FAYUVI are one-time therapies at an early stage of launch, and revenue from these products may be uneven and difficult to predict. Our product revenue may also fluctuate from period to period due to buying patterns of distributors and specialty pharmacies, reimbursement delays and pricing pressure, particularly outside the U.S. If revenue from any of these products, or our total revenue, falls short of any guidance we provide or of investor expectations, or if we do not achieve profitability on our expected timeline, the market price of our common stock could decline significantly, even if our pipeline programs advance.

Read in the 10-Q

We further expect a substantial portion of our product revenue in 2027 to come from named patient sales of GENGLYCOS and FAYUVI in countries where they are not yet approved or reimbursed. These sales depend on individual physician requests and, in many cases, on regulatory or payer approval of each request. Named patient programs vary by country and may change. Authorities may restrict or end them at any time, including after local approval or an unfavorable pricing decision. Prices may be provisional and subject to later rebates or clawbacks. Because each sale of a one-time therapy is significant, a few delayed or denied requests could materially affect our revenue in a period. If named patient sales fall short of expectations, we may not meet our guidance or achieve profitability on our expected timeline.

Read in the 10-Q

We also have reported and expect to continue to report preliminary or interim data from our clinical trials. Preliminary or interim data from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Such data may show initial evidence of clinical benefit, but as

Read in the 10-Q

Our approved gene therapies and gene therapy product candidates are complex, expensive and difficult to manufacture and demand for our approved gene therapies could exceed our supply.

Read in the 10-Q

Our ability to supply our approved gene therapy products for launch and thereafter depends on successful commercial production, release testing, quality oversight and coordination across the applicable sites. Gene therapy production can involve long lead times, specialized materials and assays, low yields, batch failures and limited ability to replace a failed lot quickly. A deviation at manufacturing sites for FAYUVI or GENGLYCOS could delay product release, deplete available inventory or interrupt supply. Changes to a manufacturing site, process, material or analytical method may require comparability work and regulatory submissions or approvals before affected product can be distributed. Such events could delay treatment, cause inventory losses, increase costs, reduce our ability to meet demand after launch, or adversely impact future demand.

Read in the 10-Q

In addition, demand for GENGLYCOS and FAYUVI could exceed our available supply. Our manufacturing capacity is limited, and long lead times may prevent us from increasing output quickly if demand exceeds our forecasts. If demand exceeds supply, we may need to delay treatment for some patients or limit supply to certain markets or programs. A shortage could harm patients, our reputation and our relationships with physicians and payers. It could also reduce our revenue and lead patients to seek other treatments.

Read in the 10-Q

GENGLYCOS and FAYUVI are each administered as a single infusion at a dose determined by the patient’s body weight. Weight-based dosing makes supply planning harder. Each patient receives a dose based on body weight, so the number of vials needed per patient varies materially. As a result, the number of patients we can treat from a given amount of inventory depends on the weights of the patients treated. If patients weigh more than we expect, our inventory, including inventory manufactured before approval, could run out sooner than we forecast. That could cause supply shortages and raise our cost of sales sooner than expected. If patients weigh less than we expect, inventory could expire before use and require write-offs.

Read in the 10-Q

Our ability to successfully launch GENGLYCOS and FAYUVI depends on identifying eligible patients and supporting specialized treatment centers.

Read in the 10-Q

GENGLYCOS and FAYUVI have received FDA approval, but we have limited experience as a company launching and commercializing gene therapies. As we expand our commercial and support teams to include additional expertise in these products, we may face complexities in our sales process and strategy and encounter difficulties allocating sufficient resources to their commercialization. We may be unable to make commercial product available, identify and support a sufficient number of qualified treatment centers, or coordinate the testing, referral, scheduling, infusion, and follow-up necessary to treat eligible patients on our anticipated timelines. Patients with GSDIa who are younger than eight years old or have certain clinical characteristics, including pre-existing antibodies to the AAV vector, may be ineligible for GENGLYCOS. FAYUVI's approved indication is limited to pediatric patients with preserved neurodevelopmental function, and patients may not be identified before their disease progresses beyond the approved population. Treatment may also require specialized personnel, monitoring, and management of immune responses and other adverse reactions. Delays or limits in patient identification, treatment-center readiness, payor authorization, supply or post-treatment care could reduce the number of patients treated, defer revenue, increase costs and prevent us from realizing our

Read in the 10-Q

expected commercial opportunity. As one-time therapies, the timing and number of eligible patients treated may cause our revenue to fluctuate, and the population of previously untreated eligible patients may decline over time.

Read in the 10-Q

the remaining ANDA filers is ongoing. See “Item 1. Legal Proceedings” above for a description of these actions. We cannot predict the outcome of our remaining suits, whether or on what terms we will reach settlements with any of the remaining ANDA filers, or whether there will be additional ANDA filings for DOJOLVI.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 18, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
• We face manufacturing and supply risks for our approved products and our product candidates, particularly as we scale commercial production of our recently approved gene therapy products.

Read it in the 10-Q at sec.gov

Show the other 22
Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Following the approvals of GENGLYCOS and FAYUVI and the failure of the GTX-102 Aspire Phase 3 study, which reduced the number of late-stage programs that may generate near-term value, we expect investors to evaluate us increasingly on the commercial performance of our approved products, with less weight on clinical and regulatory milestones. Our commercial performance depends on several products that face different risks. A substantial portion of our total revenue consists of royalty revenue from KKC's sales of CRYSVITA, which depends on KKC's commercialization efforts, which we do not control. See risk factor “We are dependent on KKC for the d commercialization of CRYSVITA in our markets, including the U.S. and Canada, and for our supply of CRYSVITA in our markets.” GENGLYCOS and FAYUVI are one-time therapies at an early stage of launch, and revenue from these products may be uneven and difficult to predict. Our product revenue may also fluctuate from period to period due to buying patterns of distributors and specialty pharmacies, reimbursement delays and pricing pressure, particularly outside the U.S. If revenue from any of these products, or our total revenue, falls short of any guidance we provide or of investor expectations, or if we do not achieve profitability on our expected timeline, the market price of our common stock could decline significantly, even if our pipeline programs advance.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
We further expect a substantial portion of our product revenue in 2027 to come from named patient sales of GENGLYCOS and FAYUVI in countries where they are not yet approved or reimbursed. These sales depend on individual physician requests and, in many cases, on regulatory or payer approval of each request. Named patient programs vary by country and may change. Authorities may restrict or end them at any time, including after local approval or an unfavorable pricing decision. Prices may be provisional and subject to later rebates or clawbacks. Because each sale of a one-time therapy is significant, a few delayed or denied requests could materially affect our revenue in a period. If named patient sales fall short of expectations, we may not meet our guidance or achieve profitability on our expected timeline.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
We also have reported and expect to continue to report preliminary or interim data from our clinical trials. Preliminary or interim data from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Such data may show initial evidence of clinical benefit, but as

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Our approved gene therapies and gene therapy product candidates are complex, expensive and difficult to manufacture and demand for our approved gene therapies could exceed our supply.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Our ability to supply our approved gene therapy products for launch and thereafter depends on successful commercial production, release testing, quality oversight and coordination across the applicable sites. Gene therapy production can involve long lead times, specialized materials and assays, low yields, batch failures and limited ability to replace a failed lot quickly. A deviation at manufacturing sites for FAYUVI or GENGLYCOS could delay product release, deplete available inventory or interrupt supply. Changes to a manufacturing site, process, material or analytical method may require comparability work and regulatory submissions or approvals before affected product can be distributed. Such events could delay treatment, cause inventory losses, increase costs, reduce our ability to meet demand after launch, or adversely impact future demand.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
In addition, demand for GENGLYCOS and FAYUVI could exceed our available supply. Our manufacturing capacity is limited, and long lead times may prevent us from increasing output quickly if demand exceeds our forecasts. If demand exceeds supply, we may need to delay treatment for some patients or limit supply to certain markets or programs. A shortage could harm patients, our reputation and our relationships with physicians and payers. It could also reduce our revenue and lead patients to seek other treatments.

Read it in the 10-Q at sec.gov

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
In particular, our operations are directly, and indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations; patient and non-patient privacy laws and regulations, including the European General Data Protection Regulation (EU) 2016/679, or GDPR, in the EEA, the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018, or the UK GDPR, in the UK, the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the California Consumer Privacy Act of 2018, or CCPA, as amended by the California Privacy Rights Act of 2020, or CPRA, and California’s Confidentiality of Medical Information Act; and the evolving global landscape for AI-related laws and regulations, which may impose obligations on companies developing that develop, deploy, or use AI systems (including through third-party vendors) and using AI may address, among other things, documentation and include U.S. federal governance requirements, transparency obligations, data sourcing and state laws quality considerations, and regulations and the EU Artificial Intelligence Act, as described above in “Item 1. other compliance measures.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs, and if we make changes to manufacturing sites, materials, methods, testing, or other aspects of our process, we may be required to demonstrate comparability or conduct additional studies or analyses to bridge product manufactured before and after such changes, which could delay development timelines and increase costs.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
For example, Similarly, in December 2025, September 2026, we announced that our UX143 Phase 3 Orbit and Cosmic studies Aspire study of GTX-102 in Angelman syndrome did not achieve their its primary endpoints despite promising Phase 2 results, endpoint or key secondary endpoints, and as a result, we are implementing initiated additional significant expense reductions. reductions in November 2026.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
While we currently expect to achieve profitability in 2027, our expectations are based on a variety of assumptions, and actual results, assumptions including whether we achieve profitability on the success of our expected timeline or at all, may materially differ gene therapy launches, continued revenue growth from our expectations. commercial products and our ability to achieve our planned expense reductions.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Serious adverse events in clinical trials involving associated with approved gene therapy product candidates therapies may damage public perception of the safety of our product candidates, perception, increase government regulation, restrict commercialization, and adversely affect our ability to obtain regulatory approvals for our product candidates or conduct our business.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
In order to obtain approval, To maintain commercial manufacturing at the facility, we will need must continue to ensure that all of our processes, quality systems, methods, equipment, policies and procedures are compliant comply with cGMP. cGMP and the conditions of the applicable approvals.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, additional legislative changes, including the impact from the Inflation Reduction Act of 2022, 2022 (including, among other things, the potential for Medicare price negotiation and related changes that could affect net pricing and reimbursement dynamics for certain products over time), and statements and actions by elected officials.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell our approved gene therapies or any products that we may develop. develop, could be required to undertake costly investigations and remediation, and could experience delays in our development programs or any commercialization activities.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
For instance, if the existing remaining ANDA filers or additional competitors are able to enter the market with generic versions of Dojolvi, DOJOLVI, or if Esjay’s or Navinta’s permitted entry date is accelerated under the terms of our respective settlement agreements, our sales of Dojolvi DOJOLVI could materially decline decline, which could have an adverse impact on our financial results.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Interference Derivation proceedings or derivation proceedings now available under the Leahy-Smith Act Act, or interference proceedings with respect to certain older patents and applications, whether provoked by third parties or parties, brought by us us, or declared or instituted by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
It is difficult to predict what CMS or private payors will decide with respect to reimbursement for products such as ours, especially our gene therapy product candidates as there is a limited body of established practices and precedents for gene therapy products.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
In addition, we may not be able to achieve the anticipated benefits or effectively realize all the cost savings anticipated from the reduction reductions in force on our expected timeline or at all, and we may incur unanticipated charges or make additional cash payments as a result of such initiatives that were not previously contemplated which could result in an adverse effect on our business or results of operations. contemplated.

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 4, 2026 vs 10-K Feb 18, 2026
Problems However, problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, noncompliance with regulatory requirements, product recalls, product liability claims or insufficient inventory.

Read it in the 10-Q at sec.govThe 10-K sentence

The first 27 of 71 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 18, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 19, 2025

strategic restructuring ×4restructuring plan ×4current administration ×4workforce reduction ×4federal agencies ×3million shares ×3performance depends ×2rates inflation ×2market instability ×2instability arising ×2trade tensions ×2government funding ×2full impact ×2regulatory submissions ×2received crl ×2cited information ×2
Where each one is used
  • strategic restructuring: •We may experience unexpected costs or not achieve our anticipated savings from our recently announced strategic restructuring plan.
  • restructuring plan: •We may experience unexpected costs or not achieve our anticipated savings from our recently announced strategic restructuring plan.
  • current administration: The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have...
  • workforce reduction: We are dependent on Emil D. Kakkis, M.D., Ph.D., our Founder, President, and Chief Executive Officer, the loss of whose services may adversely impact the achievement of our objectives. Dr. Kakkis could leave our employment at any time, as he is an “at will” employee. Recruiting and retaining other qualified...
  • federal agencies: The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have...
  • million shares: Pursuant to our 2023 Incentive Plan, as amended, or the 2023 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors, and consultants. At December 31, 2025, there were 7.9 million shares available for future grants under the 2023 Plan.
  • performance depends: •Our future financial performance depends on the successful commercialization of our products and product candidates.
  • rates inflation: Any additional fundraising efforts may divert our management’s attention from their day-to-day activities, which can adversely affect our ability to develop our product candidates and commercialize our products. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

37 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
We expect to need additional managerial, operational, marketing, financial, legal, and other resources to support our development and commercialization plans and strategies. In order to successfully commercialize our products as well as any additional products that may result from our development programs or that we acquire or license from third parties, we expect to expand our commercial team in the United States as well as in Europe, Latin America and the Asia-Pacific region. This infrastructure consists of both office-based as well as field teams with technical expertise, and is...
In the 10-K filed Feb 19, 2025
The FDA Rare Pediatric Disease Priority Review Voucher Program, or PRV Voucher Program, awards Priority Review Vouchers, or PRVs, to sponsors of rare pediatric product applications that meet certain criteria. Under the program, a company that receives an approval for a product for a rare pediatric disease (as determined by the applicable regulations) may qualify for a PRV that can be redeemed to receive Priority Review of a subsequent marketing application for a different product. PRVs may also be sold by the company to third parties. We received PRVs under the PRV Voucher Program in...
In the 10-K filed Feb 19, 2025
We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us....
In the 10-K filed Feb 19, 2025
The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we are required to perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404(a) of the Sarbanes-Oxley Act. Section 404(b) of the Sarbanes-Oxley Act also requires our independent auditors to attest to, and report on, this management assessment....
In the 10-K filed Feb 19, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.